30 billion pharmaceutical stocks and Kexing signed a new crown oral drug entrusted production agreement, the stock price was once halved | News Focus

Share to WeChat Open WeChat, click “Discover” at the bottom, Use “Scan” to share webpages to Moments.

First Financial 2022-06-06 15:46:00

Editor in charge: Hao Yunying

Xin Litai, a pharmaceutical stock with a total market value of nearly 30 billion yuan, announced that the company and Shenzhen Kexing signed an agreement on CDMO technical services and entrusted production of anti-new coronavirus small molecule oral drugs. Shenzhen Kexing entrusted Xinlitai and Huizhou Xinlitai to carry out SHEN26 project drug CDMO services and commissioned processing of APIs and preparations. SHEN26 is an antiviral drug owned by Shenzhen Kexing Pharmaceutical Co., Ltd. for the treatment of COVID-19 and other viral infections. So far, all pharmaceutical and non-clinical research work has been completed.

30 billion pharmaceutical stocks and Kexing signed a new crown oral drug entrusted production agreement, the stock price was once halved | News Focus

Xin Litai, a pharmaceutical stock with a total market value of nearly 30 billion yuan, announced that the company and Shenzhen Kexing signed an agreement on CDMO technical services and entrusted production of anti-new coronavirus small molecule oral drugs. Shenzhen Kexing entrusted Xinlitai and Huizhou Xinlitai to carry out SHEN26 project drug CDMO services and commissioned processing of APIs and preparations. SHEN26 is an antiviral drug owned by Shenzhen Kexing Pharmaceutical Co., Ltd. for the treatment of COVID-19 and other viral infections. So far, all pharmaceutical and non-clinical research work has been completed.

This content is original by Yicai, and the copyright belongs to Yicai. Without the written authorization of CBN, it may not be used in any way, including reprinting, excerpting, copying or creating mirror images. Yicai.com reserves the right to pursue legal liability of infringers. For authorization, please contact Yicai Department: 021-22002972 or 021-22002335; [email protected].